A NEW ANTIHYPERTENSIVE AGENT - MAXZIDE (75-MG TRIAMTERENE-50-MG HYDROCHLOROTHIAZIDE)

被引：0
|
作者：
BLUME, CD
WILLIAMS, RL
机构：
[1] MYLAN PHARMACEUT,MORGANTOWN,WV
[2] UNIV CALIF SAN FRANCISCO,DRUG STUDIES UNIT,SAN FRANCISCO,CA 94143
来源：
SOUTHERN MEDICAL JOURNAL | 1986年 / 79卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：74 / 74
页数：1
相关论文
共 50 条
  • [21] Comparison of the antihypertensive effects of the fixed dose combination enalapril 10 mg/nitrendipine 20 mg vs losartan 50 mg/hydrochlorothiazide 12.5 mg, assessed by 24-h ambulatory blood pressure monitoring, in essential hypertensive patients
    A de la Sierra
    B Gil-Extremera
    C Calvo
    C Campo
    J García-Puig
    E Márquez
    J Oliván
    A Roca Cusachs
    S Sanz de Castro
    C Pontes
    J Delgadillo
    Journal of Human Hypertension, 2004, 18 : 215 - 222
  • [22] Evaluation by ambulatory blood pressure measurement of the antihypertensive effect of the fixed combination therapy valsartan 80 mg and hydrochlorothiazide 12.5 mg
    Vaisse, B
    Ghobrial, H
    Vaur, L
    Poncelet, P
    Asmar, R
    Herpin, D
    Mallion, JM
    JOURNAL OF HYPERTENSION, 2001, 19 (08) : A2 - A2
  • [23] Comparison of the antihypertensive effects of the fixed dose combination enalapril 10 mg/nitrendipine 20mg vs losartan 50 mg/hydrochlorothiazide 12.5 mg, assessed by 24-h ambulatory blood pressure monitoring, in essential hypertensive patients
    de la Sierra, A
    Gil-Extremera, B
    Calvo, C
    Campo, C
    García-Puig, J
    Márquez, E
    Oliván, J
    Cusachs, AR
    de Castro, SS
    Pontes, C
    Delgadillo, J
    JOURNAL OF HUMAN HYPERTENSION, 2004, 18 (03) : 215 - 222
  • [24] BISOPROLOL FUMARATE/HYDROCHLOROTHIAZIDE 6.25 MG - A NEW LOW-DOSE OPTION FOR FIRST-LINE ANTIHYPERTENSIVE THERAPY
    DEQUATTRO, V
    WEIR, MR
    ADVANCES IN THERAPY, 1993, 10 (05) : 197 - 206
  • [25] Telmisartan plus hydrochlorothiazide (80/25 mg) has a greater antihypertensive effect than valsartan plus hydrochlorothiazide (160/25 mg) in patients with stage 1 and 2 hypertension
    White, W
    Punzi, H
    Neutel, J
    Davidai, G
    Koval, S
    Murwin, D
    AMERICAN JOURNAL OF HYPERTENSION, 2005, 18 (05) : 97A - 97A
  • [26] Antihypertensive efficacy and vasoprotective properties of a new combination of beta-blocker, bisoprolol (2,5/5 mg) and diuretic, hydrochlorothiazide (6,25 mg)
    Ostroumova, O. D.
    Sazonova, A. G.
    Reznikova, K. U.
    Srednjakov, A. V.
    Smolyarchuk, E. A.
    RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2010, 6 (01) : 48 - 52
  • [27] Antihypertensive efficacy and tolerability of candesartan-hydrochlorothiazide 32/12.5 mg and 32/25 mg in patients not optimally controlled with candesartan monotherapy
    Boenner, Gerd
    BLOOD PRESSURE, 2008, 17 : 22 - 30
  • [28] The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease
    Gurbel, Paul A.
    Bergmeijer, Thomas O.
    Tantry, Udaya S.
    ten Berg, Jurrien M.
    Angiolillo, Dominick J.
    James, Stefan
    Lindahl, Tomas L.
    Svensson, Peter
    Jakubowski, Joseph A.
    Brown, Patricia B.
    Duvvuru, Suman
    Sundseth, Scott
    Walker, Joseph R.
    Small, David
    Moser, Brian A.
    Winters, Kenneth J.
    Erlinge, David
    THROMBOSIS AND HAEMOSTASIS, 2014, 112 (03) : 589 - 597
  • [29] Comparison of the antihypertensive effects of the candesartan 8 mg-hydrochlorothiazide 12.5 mg combination (C8+H) vs the valsartan 80 mg-hydrochlorothiazide 12.5 mg combination (V80+H) in patients with essential hypertension resistant to monotherapy
    Azizi, M
    Nisse-Durgeat, S
    JOURNAL OF HYPERTENSION, 2004, 22 : S254 - S255
  • [30] Evaluation by ambulatory blood pressure measurement of the antihypertensive effect of the fixed combination therapy valsartan 80 mg and hydrochlorothiazide 12,5 mg
    Vaïsse, B
    Ghobrial, H
    Vaur, L
    Poncelet, P
    Asmar, R
    Herpin, D
    Mallion, JM
    ARCHIVES DES MALADIES DU COEUR ET DES VAISSEAUX, 2001, 94 (08): : 907 - 912
12345